Cancer Biomarkers Market
                     Cancer Biomarkers Market Information 
Type (Genetic Biomarkers, Epigenetic 
Biomarkers, Proteomic Biomarkers, 
Glycoprotein Biomarkers), Disease Type, 
Profiling Technologies and Application: 
Forecast To 2027
www.reportsanddata.com
Market Summary
According to the current analysis of Reports and Data, the global Cancer Biomarkers market was valued 
at USD 12.14 Billion in 2018 and is expected to reach USD 32.25 Billion by year 2026, at a CAGR of 
12.75%.
According to the Centre for Disease Control and Prevention (CDC), for around 22,000 men and 9,000 
women suffer from liver cancer, and around 16,000 men and 8,000 women die from liver cancer in 
United States. Cancer biomarkers are the molecules released from cancerous tumours which are found in 
blood and other tissues which can be detected by diagnosing, screening and prediction for the 
progression of the disease. 
Development of advanced genomic analysis technique, introduction of effective guidelines for 
biomarkers manufacturing, huge amount of research by Cancer societies and proven effectiveness of 
transplants are some of the primary growth stimulants for the market. Certain manufacturing and 
pharmacological issues and regulatory hurdles are hindering the growth of the market.
Development of products from research institutes has been propelling the growth of this market. For 
instance, in January 2018, Researchers from University of Luxembourg have discovered a new biomarker 
for colorectal cancer which classifies patients into “high” and “low” risk group which may help 
oncologists to choose the adequate treatment for a particular patient.
www.reportsanddata.com
Free Report Sample PDF @ https://www.reportsanddata.com/sample-enquiry-form/1422 
www.reportsanddata.com
Further key findings from the report suggest
• Cancer Biomarkers market is fastest growing at a CAGR of 7% in Asia Pacific due to high awareness 
about biomarkers and rise in aging population and even rising incidences of cancer
• The market for lung cancer disease type segment (i.e. small cell lung cancers, non-small cell lung 
cancers) is expected to hold the fastest growing CAGR because of increase in population who smoke 
and due to very low air purity
• Europe is the second largest region with a share of 28.5% due to the high cases of cancer in France, 
Ireland, etc
• Genetics Biomarkers is accounted to be the second leading segment which is valued holds a market 
share of 20.8% due to high usage and perfect accuracy rate
• Immunoassays segment is projected to have the highest CAGR among the other application type
• North America is expected to account for the 39.1% of the global Cancer Biomarkers market owing to 
the presence of high quality healthcare equipment
• Prognostics segment holds the second largest share in this market which is valued at USD 3440.8 
million due to maximum population are aware about the new technologies
www.reportsanddata.com
Segments covered in the report:
For the purpose of the study, this Reports and Data has segmented the Global Cancer Biomarkers Market 
on the basis of biomolecule type, disease type, profiling technologies, application, services and the 
regional outlook:
Biomolecule Type (Revenue, USD Million; 2016–2026)
• Genetic Biomarkers
• Epigenetic Biomarkers
• Proteomic Biomarkers
• Glycoprotein Biomarkers
Disease Type (Revenue, USD Million; 2016–2026)
• Breast Cancer
• Blood Cancer
• Lung Cancer
• Cervical Cancer
• Colorectal Cancer
• Melanoma
• Ovarian Cancer
www.reportsanddata.com
• Liver Cancer
• Stomach Cancer
Profiling Technologies (Revenue, USD Million; 2016–2026)
• Imaging technologies
• Ultrasound
• Computed Technology (CT)
• Magnetic Resource Imaging (MRI)
• Positron Emission Tomography (PET)
• Omic Technologies
• Proteomics
• Genomics
• Others
• Cytogenetics-Based Tests
• Immunoassays
• Bioinformatics
Application (Revenue, USD Million; 2016–2026)
• Risk Assessment
• Prognostics
Free Report Sample PDF @ https://www.reportsanddata.com/sample-enquiry-form/3404 
www.reportsanddata.com
• Disease Diagnosis
• Personalised Medicine
• Drug Discovery and Development
Method (Revenue, USD Million; 2016–2026)
• Sample Preparation
• Assay Development
• Biomarkers and Testing
Regional Outlook: (Revenue, USD Million; 2016–2026)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Spain
• France
• Italy
• Rest of Europe
www.reportsanddata.com
• Asia Pacific
• Japan
• China
• India
• Australia
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Middle East and Africa (MEA)
Browse Complete Report @ https://
www.reportsanddata.com/report-detail/cancer-biomarkers-market 
www.reportsanddata.com
About Us
Reports and Data is a market research and 
consulting company that provides syndicated research 
reports, customized research reports, and consulting 
services. Our solutions purely focus on your purpose to 
locate, target and analyze consumer behavior shifts 
across demographics, across industries and help client’s 
make a smarter business decision. 
Contact US
We offer market intelligence studies ensuring relevant 
and fact-based research across a multiple industries John Watson
including Healthcare, Technology, Chemicals, Power, and Head of Business Development
Energy. We consistently update our research offerings to 
ensure our clients are aware about the latest trends Reports And Data | Web: 
existent in the market. Reports and Data has a strong www.reportsanddata.com
base of experienced analysts from varied areas of Direct Line: +1-212-710-1370
expertise. E-mail: [email protected]
www.reportsanddata.com